JNJ beats Q1 estimates and lifts guidance, but Stelara's patent loss looms. Can pipeline strength and new drugs sustain its growth momentum?
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results